ClinicalTrials.gg
CompletedNCT04655729Updated Oct 28, 2026

Biomarkers to Predict and Monitor Response to Infliximab

An observational study in Crohn Disease, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 3 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Massachusetts General Hospital · Observational

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
107
Ages
3 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Crohn Disease by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Crohn Disease · Massachusetts General Hospital.

Started
2019
with 1 other
Observational
5 of 14
3 open now
Registered
8th of 14
by date

Among the 14 studies in Crohn Disease by Massachusetts General Hospital, this one is one of 2 that started in 2019, is one of 5 observational ones, and was the 8th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 14 studies in Crohn Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 3 Years to 20 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Crohn Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The aim of the study is to generate novel minimally-invasive serum protein signatures and biomarkers in children and adolescents with Crohn's Disease (CD) that correlate with and can predict and monitor patients who will have a prolonged response to Infliximab so that personalized medicine can be applied to patients with CD.

Read the detailed description

Prospective, observational study will enroll 120 unique pediatric Crohn's disease patients between the ages of 3-20 years among multiple sites. Patients will be naïve to TNF inhibitor. If patient is going to start infliximab or infliximab biosimilar, patient may be enrolled in study. Study length will be from commencement of infliximab until the infusion visit given at least 1 year after initiation. During the study, if the patient fails infliximab or biosimilar, they will be complete study once failure is indicated and discontinued on infliximab or biosimilar. Patients may be on concurrent IBD therapy such as antibiotics, mesalamines, immunomodulators and may continue in study if non-standard induction schedule or changes made during induction or maintenance to dose or frequency. Excluded patients will be those receiving infliximab or biosimilar infusions at home due to need for blood collection at time of infusion, on systemic corticosteroids (topical preparations such as budesonide are allowed), and those who have already undergone significant bowel surgery relating to their Crohn's.

Study visits will take place in conjunction with previously scheduled routine clinic visits or infusion visits. At initial study visit, demographics, medical and surgical history, PARIS classification, PCDAI, weight and height, fecal calprotectin, labs, EGD and colonoscopy report and pathology report, cross-sectional imaging reports and concurrent medications will be obtained and entered. Parameters measured at each study visit will include any obtained labs, weight and height, PARIS classification, PCDAI, infliximab dose (mg/kg) and dose interval. There will be four study visits throughout the course of 1 year after initiating infliximab. At these four visits, blood will be obtained in PAXgene tubes for RNA analysis and serum for banking for SOMAscan analysis.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
3 Years to 20 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients 3-20 years old diagnosed with Crohn's Disease starting infliximab

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between the ages of 3-20 years old
  • Patient starting infliximab or infliximab biosimilar,
  • Patients naïve to TNF inhibitor

Exclusion criteria

Exclusion Criteria:

  • Patients receiving infliximab or biosimilar infusions at home
  • Patients already undergone significant bowel surgery relating to their Crohn's.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
107 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

06

What researchers measure

Primary outcomes

  1. Define pretreatment serum protein biomarkers that predict and monitor response to TNF inhibitors (Discovery Cohort)

    Run 120 pediatric Crohn's patients' serum at baseline, week 14, and week 54 on SOMAscan; Develop predictor model for protein biomarkers that predict response from baseline serum

    Time frame: 2 years

Secondary outcomes

  1. Identify pathophysiological mechanisms associated with response or lack of response in patients receiving IFX using SOMAscan.

    Identify pathophysiological mechanisms associated with response or lack of response in patients receiving IFX using SOMAscan.

    Time frame: 2 years

  2. Use systems biology to map out pathways activated in those patients at week 14 that have clinical and laboratory response to infliximab

    Use systems biology to map out pathways activated in those patients at week 14 that have clinical and laboratory response to infliximab

    Time frame: 2 years

07

Study locations

1 site
  • MassGeneral for Children
    Boston, Massachusetts 02114, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Sep 2024, 58 months.

Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's 58 months is above that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Nov 2022 → Sep 2024 and completion Jan 2023 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 7, 2020
StartActual
Nov 18, 2019
Primary completionActual
Sep 30, 2024was Nov 2022
CompletionActual
Nov 1, 2024was Jan 2023
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 28, 2026
Primary completion
Nov 30, 2022→Sep 30, 2024 (actual)
Oct 28, 2026
Study completion
Jan 1, 2023→Nov 1, 2024 (actual)
Oct 28, 2026
Enrollment
120 (estimated)→107 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Status unknown→Completed
    Primary completion Nov 30, 2022→Sep 30, 2024 (now actual)
    Study completion Jan 1, 2023→Nov 1, 2024 (now actual)
    Enrollment 120 (estimated)→107 (actual)
    + 4 other changes: verification date, site details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04655729
Collaborators
Crohn's and Colitis Foundation
Responsible party
Harland S. Winter, MD (Director, Pediatric IBD Program, Massachusetts General Hospital) — Principal investigator
First posted
Dec 7, 2020
Start date
Nov 18, 2019
Primary completion
Sep 30, 2024
Completion
Nov 1, 2024
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion